1 January 2025 in Advances in Hematology
Sodium‐glucose Cotransporter 2 inhibitors (SGLT2i) are widely used and effective pharmacotherapeutic options that are first‐line therapy for Type 2 diabetes mellitus (T2DM) and congestive heart failure. A major adverse effect of SGLT2i usage is diabetic ketoacidosis (DKA). SGLT2i‐induced DKA commonly presents as euglycemic DKA (EDKA). The safety of empagliflozin in cancer patients is not well established. High intensity treatment of hematologic malignancy poses a unique set of risk factors for EDKA. Four cases of empagliflozin‐associated EDKA in hematologic malignancy patients were identified through pharmacy adverse event reporting at a cancer research hospital. All patients were euglycemic except one patient who required CRS/ICANS treatment with dexamethasone, causing steroid‐induced hyperglycemia. All four patients had weight loss due to reasons including, but not limited to, reduced oral intake, diarrhea, nausea, and pain. Infections and/or neutropenic fever were also commonalities throughout the four patients. In all patients, DKA contributed to iatrogenic ICU admissions and prolonged hospital stays. SGLT2i use in hematologic malignancy patients may increase the risk of DKA due to high risk of anorexia, weight loss, and infections, all highly associated with intensive treatment that can disrupt the availability and sensitivity to insulin. In patients receiving SGLT2i, clinicians should be aware of risk factors for DKA as well as potential euglycemic presentation to ensure close clinical and laboratory monitoring to facilitate rapid diagnosis and treatment of DKA.
18 August 2026 in Journal of Pharmacy Practice
Automated dispensing cabinet (ADC) overrides facilitate timely medication access but bypass standard medication-use safety checks, necessitating ongoing monitoring to identify potential risks. Many health systems rely on manual, retrospective workflows to review override activity, yet operational burden associated with these processes is not well characterized. Objectives of the evaluation were to describe the workflow, quantify the time burden, and identify limitations associated with a manual ADC override monitoring process within a large health system. This retrospective, descriptive quality improvement evaluation was conducted at a large oncology-focused health system. The existing ADC override review process was assessed over a 6-month period. Workflow steps included generation of external reports, manual alignment and manipulation of data within spreadsheets, and creation of pivot table summaries for analysis across patient care areas. Time required to complete each monthly override audit was tracked, and process limitations were documented. The mean time required to complete a monthly override audit was 1 h and 7 min, with a range of 42 min to 1 h and 55 min. The most time-intensive activities were spreadsheet construction, data manipulation, and report preparation. Additional effort was required to train and validate reviewers. Key process limitations included reliance on retrospective reporting, lack of standardized review methodologies, and challenges aggregating data to identify system-level trends. Manual ADC override monitoring is resource intensive and subject to variability due to retrospective, spreadsheet-based workflows. These findings suggest a need for optimized and standardized approaches to support medication safety surveillance and improve scalability of override review processes.